Tag : OVERALL SURVIVAL

CONFERENCE UPDATE

Osimertinib + plat-pem shows consistent OS benefits in EGFRm advanced NSCLC irrespective of poor baseline prognostic factors: Exploratory OS analyses from FLAURA2
In the phase 3 FLAURA2 study, osimertinib + platinum-pemetrexed demonstrated statistically significant improvements in progression-free survival and overall survival vs. osimertinib monotherapy in epidermal growth factor receptor-mutated advanced non-small cell lung cancer, achieving a median OS of 47.5 months.
CONFERENCE UPDATE

Alectinib prolongs OS and shows durable response in previously untreated advanced ALK+ NSCLC: Final OS analysis from the phase 3 ALEX study
The ALEX study's final analysis shows that first-line alectinib significantly improves overall survival and duration of response in untreated advanced ALK-positive non-small cell lung cancer (NSCLC) compared to crizotinib, reinforcing alectinib as the standard of care for these patients.

Professor Mok Shu Kam Tony

Chairman, Department of Clinical Oncology, The Chinese University of Hong Kong
CONFERENCE UPDATE

Adjuvant abemaciclib + ET reduces risk of death in HR+, HER2-, high-risk early breast cancer: Primary OS results from the monarchE trial
The monarchE trial reveals that adjuvant abemaciclib combined with endocrine therapy significantly enhances overall survival (OS) and invasive disease-free survival in patients with high-risk, hormone receptor-positive, HER2-negative early breast cancer, establishing this regimen as a new standard of care.

Professor Stephen Johnston

The Royal Marsden, NHS Foundation Trust, London, United Kingdom
CONFERENCE UPDATE

Investigating the association between pretreatment thrombocytosis and ovarian cancer recurrence and survival
Thrombocytosis is frequently observed among cancer patients and can be attributed to increased platelet production. While the underlying pathophysiology has not been completely elucidated, it is believed that platelet activation is essential for tumor progression due to the release of several platelet-derived growth factors that can promote cellular proliferation, neo-vascularization, and ultimately tumor growth, tissue invasion, and metastasis.
CONFERENCE UPDATE

Final analysis of NORA demonstrates the OS benefits of niraparib maintenance in Chinese PSROC patients regardless of gBRCAm status
Niraparib is a potent and highly selective poly-ADP ribose polymerase (PARP) inhibitor. PARP inhibitors have shown a trend of favorable overall survival (OS) in platinum-sensitive recurrent ovarian cancer (PSROC) in the maintenance setting. However, this OS benefit appears inconsistent in patients without BReast CAncer gene (BRCA) mutations which has been attributed to confounding factors, such as post-progression therapies.
CONFERENCE UPDATE

HRQoL improvements with pembrolizumab + CCRT and EBRT in high-risk LACC patients in ENGOT-CX11/GOG-3047/KEYNOTE A18
CONFERENCE UPDATE

Validating PFS as a surrogate marker for OS in endometrial cancer treatment assessment: Results from an EORTC-YGCG systemic review
Progression-free survival (PFS) is often utilized as an indicator of the overall survival (OS) of patients with endometrial cancer (EC) to facilitate regulatory approval for novel medical treatments. Nevertheless, its role as a surrogate marker for the survival outcomes of EC patients remains controversial among medical practitioners, with some questioning its reliability and suggesting its inability to reflect the eventual endpoint of the disease. To investigate PFS surrogacy on OS among patients with recurrent and advanced EC, the European Organization For Research and Treatment of Cancer Young Gynaecologic Cancer Group (EORTC-YGCG) conducted a systematic review of randomized phase 2 and 3 clinical trials in advanced/recurrent EC. During ESGO 2024 Congress, Dr. Ramon Yarza from the Royal Marsden Hospital, London, the United Kingdom, shared the findings of this review.